Anti-inflammatory |
RAW 264.7 macrophages |
The whole dried plant/water/ethanol extracts |
/ |
60 mg/mL |
Inhibiting NO and TNF-α production |
[52] |
RAW 264.7 macrophages |
The whole plant/quercetin |
/ |
2.5, 5, 10, 20 μg/ml |
Inhibiting NO production and the protein expression of iNOS and COX-2 in a dose-dependent manner |
[7] |
Xylene-induced ear edema mice |
The whole plant/water extracts |
Intragastric administration |
0.5, 1.0 mg/kg b/w |
Reducing the extent of ear edema |
[55] |
Collagen-induced arthritis mice |
The whole plant/quercetin |
Intragastric administration |
50, 100 mg/kg b/w |
Inhibiting ankle mitochondrial dysfunction and mitochondrial oxidative stress |
[4] |
Antioxidant |
DPPH radical |
The whole dried plant/water/ethanol extracts |
/ |
60 mg/mL |
Exhibiting good free radical scavenging ability |
[52] |
yeast model |
The whole dried plant/water/ethanol extracts |
/ |
60 mg/mL |
Showing higher survival rates |
[52] |
DPPH radical |
Dried stem/the crude polysaccharide extract |
/ |
10 mg/mL |
Exhibiting significant scavenging ability, with scavenging capacities more than 400 µM ascorbate equiv/g |
[68] |
Saccharomyces cerevisiae BY4734 |
Dried stem/the purified polysaccharide |
/ |
10 mg/mL |
TCP-2, TCP-3, UC-1 and UC-2 displaying significant antioxidant activity |
[68] |
Anticancer |
Human colorectal cancer cell lines HCT116 and SW480 |
The whole plant/70% ethanol extracts |
/ |
25, 50, 100 μg/ml |
Inhibiting human colorectal cancer cells through GSK3β-dependent cyclin D1 degradation |
[73] |
Human colon cancer HT-29 cells |
Taxilli heba/water extracts |
/ |
0, 0.5, 1, 2, 4, 8 g/mL |
Inhibiting the proliferation, invasion, and migration of human colon cancer cells via the PI3K/AKT signaling pathway |
[74] |
Human leukemia cell lines HL-60 and K562 |
The whole plant/extracts |
/ |
50, 100, 200, 400 μg/ml |
Inhibiting cell proliferation |
[75] |
Human leukemia U937 cells |
Quercetin |
/ |
10, 20 μM |
Promoting the reversible G2/M phase arrest of U937 cells |
[80] |
Myeloid cell line P39 |
Quercetin |
/ |
10, 50, 100 μM |
Decreasing expression of BcL2, BcL-xL and McL-1 expression, increasing Bax expression |
[81] |
Liver cancer cells (HuH-7 cells, HepG-2 cells) |
Procyanidin B1 |
/ |
0, 5, 50, 500 μM |
Inhibiting the Kv10.1 channel in a concentration-dependent manner |
[82] |
Xenograft mice |
Procyanidin B1 |
Subcutaneous injection |
15 mg/kg b/w |
Inhibiting the growth of the tumor |
[82] |
MCF-7 and MDA-MB-231 breast cancer cell lines |
Procyanidin C1 |
/ |
6.25 ~ 100 μg/mL |
Inducing DNA damage, arresting the cell cycle, Decreasing Bcl-2 levels, and increasing the expression of BAX, caspase 3 and 9 in cells |
[83] |
Human liver cancer cells Bel-7402 and human stomach cancer cells MGC-823 |
Lectins |
/ |
6.25, 12.5, 25, 50, 100, 200 μg/mL |
Inhibiting the growth of cells |
[86] |
Antimicrobial and anti-virus |
Vero E6 cells |
The dried stem, with leave of the plant/water–ethanol extracts |
/ |
0, 25, 50, 100, 200 μg/mL |
Inhibiting SARS-CoV 3CL protease activity |
[87] |
HBsAg |
The whole plant/10% water extract |
/ |
20, 40, 80, 150, 300, 600, 1200, 2500 μg/50 μL |
Exhibiting good inhibitory effect on HbsAg |
[88] |
DHBV-infected ducklings |
Chlorogenic acid, caffeic acid, quinic acid |
Intragastric administration |
100 mg/kg b/w |
Reducing the DHBV viremia |
[89] |
Diuretic |
Anesthetized dogs |
Avicularin |
Intravenous injection |
0.5 mg/kg b/w |
Exhibiting diuresis |
[95, 96] |
Rats |
Avicularin |
Intragastric administration or injection |
34 mg/kg b/w |
Exhibiting significant diuretic effect |
[95, 96] |
Anti-hypertensive |
Spontaneously hypertensive rats |
Taxilli herba |
Intragastric administration |
1.48, 5.90 g/kg b/w |
Increasing SOD activity, increasing NO release in serum, and decreasing AngII and ET-1 levels in plasma |
[102] |
Renal hypertensive rats |
Quercetin |
Intragastric administration |
30 mg/kg b/w |
Decreasing blood pressure, reducing the concentration of free calcium ions in renal artery smooth muscle cells |
[103] |
Anti-hyperglycemic |
Hyperglycemia mice induced by streptozotocin |
Total flavonoids |
Intragastric administration |
100, 200, 400 mg/kg b/w |
Reducing the serum TC and TG levels and increase the serum HDL-G content of mice |
[107] |
Diabetic mice induced by streptozotocin (STZ) |
Total flavonoids |
Intragastric administration |
150, 300, 600 mg/kg b/w |
Inhibiting lipid peroxidation in mice, protecting thymus atrophy and improving insulin resistance in diabetic mice |
[108] |
HepG 2 cells |
Taxilli herba |
/ |
0.1, 0.01, 0.001 mg/mL |
Promoting the metabolism of peripheral tissues and improving the sensitivity of liver cells to insulin |
[109] |
Type 2 diabetes mellitus (T2DM) model mice |
The dried plant/Ethanol extract |
Intragastric administration |
7.5, 15, 30 g/kg b/w |
Improving high blood glucose level, liver and kidney complications, and protecting liver and kidney function |
[110] |